Power Law company profile

Synthorx

Biotech & Life Sciences · San Diego, United States · Founded 2014 · IPO 2018 Unicorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation

$2.50B

Market cap · 2026

Investors

5 investors on Synthorx's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series A 2 investors entered at this stage

Avalon Ventures

Correlation Ventures

Series B+ 3 investors entered at this stage

RA Capital Management

OrbiMed

Medicxi

Patent intelligence

$32M patent portfolio · 30 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.

Estimated portfolio value

$32M

1.3% of market cap · 523.4× the top peer Tourmaline Bio ($60k)

30 active patent families

Where Synthorx innovates InterleukinPharmaceutical drugBiochemistryMolecular biologyPharmacology

Above peer median on Strategic, Market

Quality vs same-sector peers

Synthorx on the five Patsnap quality dimensions

Synthorx in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.

Compare against

Patent quality scores (0–100)

Source: Dealroom Patent Intelligence · Patsnap

Tech-focus vs peers

Where Synthorx concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across Synthorx and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See Synthorx on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo